Study #2019-0605
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6
MD Anderson Study Status
Not Accepting
Treatment Agent
CPI-613
Description
The purpose of this study is to test any good and bad effects of the study drug, CPI-613.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Lymphoma, Leukemia
Study phase:
Phase II
Physician name:
Ranjit Nair
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-888-258-1113
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.